All In Biotech

NDA 021346 · Janssen Pharms

Risperdal Consta

Risperidone · Intramuscular

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Oct 29, 2003

Approved uses

4

Original approval plus efficacy supplements

Registered trials

514

127 Phase 3, 14 recruiting

FAERS reports

75,399

55,531 serious, 6,676 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL CONSTA is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL CONSTA is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Nov 5, 2025.

RISPERDAL CONSTA is an atypical antipsychotic indicated: for the treatment of schizophrenia. ( 1.1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder. ( 1.2 ) 1.1 Schizophrenia RISPERDAL CONSTA (risperidone) is indicated for the treatment of schizophrenia [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder RISPERDAL CONSTA is indicated as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder [see Clinical Studies (14.2 , 14.3) ] .

Mechanism: The mechanism of action of risperidone in schizophrenia is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major active metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology (12.3) ] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone [see Clinical Pharmacology (12.1) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • RISPERDAL CONSTA · RISPERIDONE 37.5MG/VIAL · POWDER, INTRAMUSCULAR · Prescription · TE AB
  • RISPERDAL CONSTA · RISPERIDONE 50MG/VIAL · POWDER, INTRAMUSCULAR · Prescription · TE AB
  • RISPERDAL CONSTA · RISPERIDONE 25MG/VIAL · POWDER, INTRAMUSCULAR · Prescription · TE AB
  • RISPERDAL CONSTA · RISPERIDONE 12.5MG/VIAL · POWDER, INTRAMUSCULAR · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gynaecomastia10,050
  • off label use6,177
  • drug ineffective5,775
  • weight increased4,872
  • drug interaction3,355
  • abnormal weight gain3,128
  • product use in unapproved indication3,031
  • emotional disorder3,005
  • condition aggravated2,577
  • somnolence2,450
  • toxicity to various agents2,312
  • extrapyramidal disorder2,244

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004541
2005678
2006935
2007851
20081,012
20091,662
20101,654
20112,063
20122,326
20131,886
20142,264
20157,746
20166,152
20177,820
20185,097
20195,327
20204,534
20214,078
20224,181
20233,896
20243,917
20253,858
20262,920

Recalls

1 FDA enforcement reports for this application.

  • Sep 11, 2013 · Class II · Terminated

    Non-Sterility: Janssen is recalling one lot of Risperdal CONSTA (risperiDONE) due to a sterility failure in a stability sample

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Risperdal Consta (Risperidone Microspheres)

2024 spending

$115M

Beneficiaries

8,313

83,485 claims

Per beneficiary

$13,806

$981.65 per unit

View as table
YearSpending
2020$212,770,026
2021$201,621,101
2022$191,210,958
2023$181,758,052
2024$114,772,775

Part B: Risperdal Consta* (Risperidone Microspheres*) · HCPCS J2794

2024 spending

$2.0M

Beneficiaries

263

2,607 claims

Per beneficiary

$7,484

2024 ASP limit $11.95 per unit

View as table
YearSpending
2020$3,899,552
2021$3,340,583
2022$2,852,736
2023$2,569,863
2024$1,968,421

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,258 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.